Ultragenyx Pharmaceutical (RARE) Earnings Date, Estimates & Call Transcripts $48.86 -0.23 (-0.47%) (As of 12/11/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ultragenyx Pharmaceutical Latest Earnings SummaryActual EPS (Nov. 5) -$1.40 Beat By $0.05 Consensus EPS (Nov. 5) -$1.45 Ultragenyx Pharmaceutical released Q3 2024 earnings on November 5, 2024, reporting an EPS of -$1.40, which topped analysts' consensus estimates of -$1.45 by $0.05. Quarterly revenue rose 42.3% year-over-year to $139.49 million, above analyst estimates of $135.28 million. With a trailing EPS of -$6.47, Ultragenyx Pharmaceutical's earnings are expected to grow next year, from ($6.20) to ($5.11) per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckPowered by Get Ultragenyx Pharmaceutical Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ultragenyx Pharmaceutical and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRARE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RARE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Timothy SykesWARNING: Don’t let the national media distract you Millions of traders could get blindsided by this election-year shock on December 18th… And if you do nothing now, you could wind up panicking in the next 30 days… or worse, making a costly mistake.Click here to watch his emergency briefing >>> Ultragenyx Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$1.49-$1.44-$1.47Q2 20242-$1.70-$1.37-$1.54Q3 20242-$1.58-$1.22-$1.40Q4 20243-$1.41-$1.09-$1.29FY 20249-$6.18-$5.12-$5.69Q1 20253-$1.47-$1.06-$1.24Q2 20253-$1.38-$1.11-$1.21Q3 20253-$1.33-$0.97-$1.11Q4 20253-$1.26-$0.84-$1.02FY 202512-$5.44-$3.98-$4.58Q1 20261-$0.29-$0.29-$0.29 Ultragenyx Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/5/2024Q3 2024-$1.45-$1.40+$0.05-$1.40$135.28M$139.49M8/1/2024Q2 2024-$1.64-$1.52+$0.12-$1.52$123.20M$147.03M5/2/2024Q1 2024-$1.72-$2.03 -$0.31-$2.03$116.03M$108.83M2/15/2024Q4 2023-$1.65-$1.52+$0.13-$1.52$119.38M$127.39M11/2/2023Q3 2023-$2.08-$2.23 -$0.15-$2.23$99.38M$98.05M8/3/2023Q2 2023-$2.11-$2.25 -$0.14-$2.25$107.10M$108.30M Get the Latest News and Ratings for RARE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$1.97-$2.33 -$0.36-$2.33$103.90M$100.50M2/16/2023Q4 2022-$2.03-$2.16 -$0.13-$2.16$105.11M$103.35M Ultragenyx Pharmaceutical Earnings - Frequently Asked Questions When did Ultragenyx Pharmaceutical announce their last quarterly earnings? Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earning data on Tuesday, November 5, 2024. Learn more on RARE's earnings history. What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical updated its FY 2024 earnings guidance on Tuesday, November, 5th. The company issued revenue guidance of $530.0 million-$550.0 million, compared to the consensus revenue estimate of $536.8 million. Did Ultragenyx Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) reported ($1.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.45) by $0.05. Learn more on analysts' earnings estimate vs. RARE's actual earnings. How can I listen to Ultragenyx Pharmaceutical's earnings conference call? The conference call for Ultragenyx Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read Ultragenyx Pharmaceutical's conference call transcript? The conference call transcript for Ultragenyx Pharmaceutical's latest earnings report can be read online. Read Transcript How much revenue does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded annual revenue of $434.25 million. How much profit does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded net income of -$606.64 million. RARE has generated -$6.47 earnings per share over the last four quarters. What is Ultragenyx Pharmaceutical's EPS forecast for next year? Ultragenyx Pharmaceutical's earnings are expected to grow from ($6.20) per share to ($5.11) per share in the next year. More Earnings Resources from MarketBeat Related Companies MRNA Earnings VTRS Earnings GMAB Earnings SMMT Earnings SRPT Earnings RDY Earnings PCVX Earnings CTLT Earnings QGEN Earnings ROIV Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report WARNING: Don’t let the national media distract you (Ad)Millions of traders could get blindsided by this election-year shock on December 18th… And if you do nothing now, you could wind up panicking in the next 30 days… or worse, making a costly mistake.Click here to watch his emergency briefing >>> This page (NASDAQ:RARE) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredWant to Start Investing? It’s Easier Than You Think!Many people think you need a lot of money to start investing—but that’s simply not true. Andy Tanner, Rich ...The Cashflow Academy | SponsoredWARNING: Don’t let the national media distract you Millions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts